Mohammad Ismail
Internal Medicine · Anniston, ALNPI 1700811072
Payments from drug & device makers
Across 145 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$636
- Novo Nordisk$330
- Teva Pharmaceuticals USA, Inc.$238
- Amgen$195
- Lilly USA, LLC$108
- Novartis$100
- plus $900 from 27 others
What the payments were for
- Food & beverage$2,45398%
- Education$552%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $636 |
| Novo Nordisk | 13 | $330 |
| Teva Pharmaceuticals USA, Inc. | 12 | $238 |
| Amgen | 10 | $195 |
| Lilly USA, LLC | 6 | $108 |
| Novartis | 6 | $100 |
| Avanir Pharmaceuticals, Inc. | 5 | $82 |
| Pfizer | 4 | $81 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $67 |
| Johnson & Johnson | 4 | $58 |
| Sanofi-aventis U.S. LLC | 3 | $57 |
| Mylan Specialty L.p. | 3 | $45 |
| Hikma Pharmaceuticals USA | 3 | $43 |
| Merck | 3 | $43 |
| Boehringer Ingelheim | 2 | $37 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| E.r. Squibb & Sons, L.L.C. | 1 | $35 |
| Dexcom, Inc. | 2 | $33 |
| Celltrion USA Inc. | 1 | $32 |
| Amarin Pharma, Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $24 |
| GSK | 1 | $23 |
| Shield Therapeutics Inc | 1 | $21 |
| Intra-sana Laboratories | 1 | $20 |
| Bayer | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Phadia US Inc. | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| UCB, Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| AstraZeneca | 1 | $12 |
How this compares
$2,507 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 156 | $90,124 |
| OzempicSemaglutide | 45 | $49,854 |
| JardianceEmpagliflozin | 41 | $45,774 |
| XareltoRivaroxaban | 35 | $38,208 |
| JanuviaSitagliptin Phosphate | 17 | $25,813 |
| TrulicityDulaglutide | 26 | $23,322 |
| LinzessLinaclotide | 23 | $23,299 |
| FarxigaDapagliflozin Propanediol | 15 | $17,129 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $12,156 |
| TradjentaLinagliptin | 13 | $11,230 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 15 | $8,543 |
| Theo-24Theophylline Anhydrous | 11 | $4,701 |
| Rosuvastatin Calcium | 111 | $3,919 |
| Ondansetron Hcl | 28 | $3,344 |
| Atorvastatin Calcium | 217 | $2,882 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $81 | $90,124156 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $37 | $65,54669 claims |
| Novo NordiskOzempic | $330 | $49,85445 claims |
| Johnson & JohnsonXarelto | $58 | $38,20835 claims |
| MerckJanuvia | $43 | $25,81317 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $108 | $24,63049 claims |
| AbbVieLinzess | $636 | $23,29923 claims |
| AstraZenecaFarxiga | $12 | $17,12915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Anniston
- Almena FreeAnniston$12.7M
- Harry StuddardMobile$12.9M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
- William KirbyBirmingham$2.3M
- Saadat AnsariHuntsville$2.1M
- Gregory FlippoTrussville$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.